Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
2000 1
2001 1
2002 2
2003 1
2005 2
2010 1
2011 1
2012 2
2013 1
2014 1
2015 2
2016 1
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Monoclonal Polymorphic Post-Transplant Lymphoproliferative Disorder"
Page 1
Post-transplant lymphoproliferative disorders.
Singavi AK, Harrington AM, Fenske TS. Singavi AK, et al. Cancer Treat Res. 2015;165:305-27. doi: 10.1007/978-3-319-13150-4_13. Cancer Treat Res. 2015. PMID: 25655616 Review.
Post-transplant lymphoproliferative disorders (PTLD) are a serious complication after solid organ or allogeneic hematopoietic stem cell transplantation and include a range of diseases from benign proliferations to malignant lymphomas. ...The World Heal …
Post-transplant lymphoproliferative disorders (PTLD) are a serious complication after solid organ or allogeneic …
Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Wang L, Yuan LL, Zeng ZG. Liu Y, et al. Int J Clin Pract. 2021 Apr;75(4):e13843. doi: 10.1111/ijcp.13843. Epub 2020 Dec 14. Int J Clin Pract. 2021. PMID: 33222369
OBJECTIVE: The purpose of this study was to analyse the clinical and pathological characteristics, treatments and outcomes of post-transplant lymphoproliferative disorder (PTLD) in paediatric liver transplant recipients. ...Three cases were classified …
OBJECTIVE: The purpose of this study was to analyse the clinical and pathological characteristics, treatments and outcomes of post- …
Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Jagadeesh D, Woda BA, Draper J, Evens AM. Jagadeesh D, et al. Curr Treat Options Oncol. 2012 Mar;13(1):122-36. doi: 10.1007/s11864-011-0177-x. Curr Treat Options Oncol. 2012. PMID: 22241590 Review.
Post transplant lymphoproliferative disorder (PTLD) is a heterogeneous disease that may occur in recipients of solid organ transplants (SOT) and hematopoietic stem cell transplant. ...In addition, recent data have emerged, including HLA and cytokine ge …
Post transplant lymphoproliferative disorder (PTLD) is a heterogeneous disease that may occur in recipients of s …
Immunosurveillance, immunodeficiency and lymphoproliferations.
Oertel SH, Riess H. Oertel SH, et al. Recent Results Cancer Res. 2002;159:1-8. doi: 10.1007/978-3-642-56352-2_1. Recent Results Cancer Res. 2002. PMID: 11785833 Review.
Although there are some differences between these immunodeficiency-associated lymphoproliferative disorders (IALD), they share several features: a tendency to present in extranodal sites, particularly the central nervous system and gastrointestinal tract, rapid clin …
Although there are some differences between these immunodeficiency-associated lymphoproliferative disorders (IALD), they share …
Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM. Weinberg OK, et al. Clin Transplant. 2023 Dec;37(12):e15134. doi: 10.1111/ctr.15134. Epub 2023 Sep 29. Clin Transplant. 2023. PMID: 37772613
BACKGROUND: Programmed cell death ligand 1 (PD-L1) expression on tumor cells engages the PD-1 receptor on T cells, inhibiting anti-tumor responses. PD-L1 has been detected in cases of post-transplant lymphoproliferative disorder (PTLD) but reports are …
BACKGROUND: Programmed cell death ligand 1 (PD-L1) expression on tumor cells engages the PD-1 receptor on T cells, inhibiting anti-tumor res …
Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB, Song QJ, Chen YX, Chen YH, Shen DH. Chen DB, et al. Int J Hematol. 2013 Jan;97(1):117-24. doi: 10.1007/s12185-012-1244-1. Epub 2012 Dec 20. Int J Hematol. 2013. PMID: 23255160
Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of solid-organ transplantation (SOT) and bone marrow transplantation, and are associated with high mortality. PTLDs represent a heterogeneous group of …
Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of solid-organ …
Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
Spasojević-Dimitrijeva B, Peco-Antić A, Paripović D, Kruscić D, Krstić Z, Cupić M, Cvetković M, Milosevski-Lomić G, Kostić M. Spasojević-Dimitrijeva B, et al. Srp Arh Celok Lek. 2014 Jan-Feb;142(1-2):83-8. doi: 10.2298/sarh1402083s. Srp Arh Celok Lek. 2014. PMID: 24684038 Free article.
INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of diseases, characterized by abnormal lymphoid proliferation following transplantation. ...The 2008 World Health Organization classification for lymphoid malign …
INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of diseases, characte …
Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH. Chen DB, et al. J Clin Pathol. 2021 Nov;74(11):697-703. doi: 10.1136/jclinpath-2021-207492. Epub 2021 May 19. J Clin Pathol. 2021. PMID: 34011618
To describe the clincopathological features and evaluate risk factors of post-transplant lymphoproliferative disorder (PTLD) after allogeneic haematopoietic stem cell transplants (allo-HSCT), with comparison between paediatric and adult .Clinicopatholo …
To describe the clincopathological features and evaluate risk factors of post-transplant lymphoproliferative disorde …
Post-transplant Lymphoproliferative Disorder in a Patient After Kidney Transplant, 5-Year Follow-up: A Case Report.
Ignacak E, Sułowicz J, Giza A, Cieniawski D, Kuźniewski M, Sułowicz W. Ignacak E, et al. Transplant Proc. 2020 Oct;52(8):2517-2519. doi: 10.1016/j.transproceed.2020.02.083. Epub 2020 Mar 26. Transplant Proc. 2020. PMID: 32222386 Free article.
INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is a serious, life-threatening complication in organ transplant patients receiving immunosuppressive therapy. ...Physical examination demonstrated tenderness in the area of the cecum, an …
INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is a serious, life-threatening complication in …
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dörken B, Riess HB. Oertel SH, et al. Am J Transplant. 2005 Dec;5(12):2901-6. doi: 10.1111/j.1600-6143.2005.01098.x. Am J Transplant. 2005. PMID: 16303003 Free article. Clinical Trial.
Post-transplant lymphoproliferative disorders (PTLD) are a life-threatening complication following solid organ transplantation. Treatment with rituximab, a humanized anti-CD20 monoclonal antibody, has proved to be a promising approach and shown …
Post-transplant lymphoproliferative disorders (PTLD) are a life-threatening complication following solid organ t …
21 results